Alumis

US · ALMS #3337 by market cap Listed 2024

6.77 -0.16 -2.31%

Live - 5344 symbols - heartbeat 130s ago · 2026-10-08 09:18

Pre-market 6.88 +1.62%

After-hours 6.77 0.00%

Overnight 6.72 -0.74%

Market cap: 876.28M
P/E (TTM): -1.65
P/B: 1.94
EPS: -2.86
Div yield: 0.00%
52W pos: 9%

Reader sentiment Are you bullish or bearish on ALMS?

Anonymous reader poll. Unscientific, not investment advice.

About Alumis

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Founded: 2021
CEO: Mr. Martin Babler
Employees: 224
Headquarters: San Francisco, California, United States of America
Fiscal year end: 12-31
Website: alumis.com

Company profile

Exchange: US
Symbol: ALMS
Market-cap rank: #3337
Listing date: 2024-06-28
Market cap: 876.28M
Float cap: 657.88M
Shares out: 129.44M
Float shares: 97.18M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 09:18:15 · For reference only, not investment advice and not tailored to your situation.